Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Finanzdaten 2006-2025 | ISKJ

Schlüsselkennzahlen Институт стволовых клеток человека

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Operating Cash Flow Per Share	4.69	2.53	3.51	0.718	2.34	0.259	-0.262	0.481	0.061	0.51	1.1	-0.355	0.589	0.002	0.731	0.498	0.082	-
Free Cash Flow Per Share	2.48	0.971	1.59	-0.423	-0.274	-0.212	-3.1	-0.412	-0.196	0.072	0.64	-1.02	0.163	-0.141	0.549	0.187	-0.041	-
Cash Per Share	6.17	3.25	2.73	1.7	2.54	2.73	1.72	5.04	2.8	2.77	1.47	0.356	0.243	1.17	2.57	0.07	0.087	-
Price To Sales Ratio	5.23	5.89	7.78	2.64	1.17	0.926	1.74	3.47	2.52	2.3	3.48	3.22	3.17	4.01	5.94	9.17	13.6	-
Dividend Yield	-	-	-	-	-	-	-	0.016	-	-	-	-	-	0.01	0.01	0.004	-	-
Payout Ratio	-	-	-	-	-	-	-	-0.191	-	-	-	-	-	1.12	0.194	0.497	-	-
Revenue Per Share	14.8	13.1	14.8	14.5	11.1	8.6	6.59	5.2	4.14	4.79	5.6	4.22	3.67	3.21	2.44	1.58	1.06	-
Net Income Per Share	1.82	0.531	0.419	1.38	1.13	-0.456	-1.37	-1.48	-0.687	-0.176	0.196	-2	0.256	0.112	0.737	0.11	0.1	-
Book Value Per Share	10.5	6.56	5.76	5.53	4.94	1.62	1.71	3.18	4.79	5.63	4.83	8.94	11.4	3.24	3.25	0.281	0.227	-
Tangible Book Value Per Share	8.62	-1.92	-1.03	-0.587	-0.655	-2.6	0.276	2.39	4.16	4.95	4.34	8.28	11	3.19	3.23	0.259	0.225	-
Shareholders Equity Per Share	5.39	3.92	2.93	2.59	1.32	0.36	0.683	2.05	3.83	4.52	4.69	8.77	11.3	3.21	3.23	0.258	0.202	-
Interest Debt Per Share	8.48	10.3	8.35	7.05	6.21	5.4	5.93	4.98	1.64	1.48	1.97	2.06	0.152	0.005	0.006	0.053	0.001	-
Market Cap	7.15 B	6.7 B	9.19 B	2.86 B	974 M	597 M	862 M	1.35 B	784 M	825 M	1.46 B	1.02 B	830 M	772 M	870 M	887 M	891 M	-
Enterprise Value	7.4 B	7.33 B	9.62 B	3.24 B	1.31 B	907 M	1.17 B	1.41 B	848 M	853 M	1.57 B	1.14 B	823 M	702 M	716 M	886 M	886 M	-1.63 M
P/E Ratio	42.4	145	274	27.7	11.5	-17.5	-8.41	-12.2	-15.2	-62.5	99.1	-6.8	45.4	115	19.6	132	145	-
P/OCF Ratio	16.5	30.4	32.7	53.1	5.55	30.7	-43.9	37.6	170	21.6	17.7	-38.3	19.7	6.71 K	19.8	29.1	177	-
P/FCF Ratio	31	79.4	72.1	-90.2	-47.5	-37.5	-3.71	-43.8	-53.3	154	30.4	-13.3	71.1	-91.3	26.4	77.5	-357	-
P/B Ratio	14.3	19.6	39.2	14.7	9.87	22.1	16.8	8.8	2.72	2.43	4.15	1.55	1.03	4	4.49	56.2	71.8	-
EV/Sales	5.4	6.45	8.14	2.99	1.57	1.41	2.37	3.62	2.73	2.37	3.74	3.61	3.14	3.65	4.89	9.16	13.5	-
EV/EBITDA	22.7	48.7	59.6	15.6	6.45	7.09	-432	-14.3	-14.4	23	24.4	105	32	44.6	13.3	80.5	99.6	-
EV/OCF	17	33.3	34.2	60.2	7.45	46.7	-59.5	39.2	184	22.3	19	-42.9	19.5	6.11 K	16.3	29	176	-
Earnings Yield	0.024	0.007	0.004	0.036	0.087	-0.057	-0.119	-0.082	-0.066	-0.016	0.01	-0.147	0.022	0.009	0.051	0.008	0.007	-
Free Cash Flow Yield	0.032	0.013	0.014	-0.011	-0.021	-0.027	-0.27	-0.023	-0.019	0.007	0.033	-0.075	0.014	-0.011	0.038	0.013	-0.003	-
Debt To Equity	1.57	2.44	2.63	2.51	4.3	13.9	8.09	2.25	0.399	0.292	0.367	0.227	0.013	0.0	0.0	0.191	-	-
Debt To Assets	0.309	0.407	0.355	0.323	0.303	0.333	0.393	0.333	0.138	0.123	0.177	0.149	0.011	0.0	0.0	0.046	-	-
Net Debt To EBITDA	0.743	4.18	2.63	1.83	1.65	2.42	-113	-0.615	-1.09	0.755	1.72	11.3	-0.269	-4.44	-2.87	-0.119	-0.599	-
Current Ratio	1.99	1.74	1.77	1.04	1.05	1.15	0.705	1.18	0.863	0.895	0.662	0.817	1.02	1.47	2.41	0.409	1	0.951
Interest Coverage	-	1.64	1.82	3.66	4.34	3.88	-1.89	-5.31	-11	-4.29	2.31	-2.17	40.2	23.5	77	28.9	183	-
Income Quality	2.58	9.55	8.37	0.521	1.58	-1.06	0.179	-0.275	-0.074	-2.3	4.95	0.187	2.19	0.012	0.878	3.56	0.626	-
Sales General And Administrative To Revenue	0.047	0.028	0.027	0.024	0.049	0.04	0.045	0.168	0.113	0.13	0.047	0.033	0.03	0.052	0.061	0.097	0.127	-
Intangibles To Total Assets	0.069	0.36	0.312	0.304	0.3	0.281	0.102	0.057	0.057	0.063	0.051	0.049	0.029	0.01	0.006	0.021	0.003	0.006
Capex To Operating Cash Flow	0.47	0.617	0.546	1.59	1.12	1.82	-10.8	1.86	4.2	0.859	0.418	-1.89	0.723	74.5	0.25	0.625	1.5	-
Capex To Revenue	0.149	0.12	0.13	0.079	0.235	0.055	0.43	0.171	0.062	0.091	0.082	0.159	0.116	0.045	0.075	0.197	0.115	-
Capex To Depreciation	2.88	2.54	1.89	1.14	3.27	1.19	5.26	2.79	0.737	1.31	1.53	5.59	5.02	1.72	3.08	8.59	9.25	-
Stock Based Compensation To Revenue	0.001	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Graham Number	14.9	6.84	5.26	8.96	5.78	1.92	4.58	8.28	7.7	4.23	4.55	19.9	8.07	2.85	7.32	0.799	0.674	-
Return On Invested Capital, ROIC	0.114	0.049	0.077	0.142	0.187	0.052	-0.092	-0.209	-0.197	9.86	0.053	-0.014	0.02	0.025	0.124	0.238	0.392	-
Return On Tangible Assets, ROTA	0.071	0.035	0.028	0.098	0.086	-0.042	-0.109	-0.114	-0.066	-0.017	0.021	-0.157	0.019	0.023	0.163	0.105	0.167	-
Graham Net Net	-8.86	-12.4	-11.7	-11.4	-10	-9.72	-9.79	-5.21	-3.16	-2.01	-3.32	-3.71	-1.94	-0.428	1.32	-0.69	-0.27	-
Working Capital	556 M	294 M	286 M	19.8 M	22.2 M	61 M	-165 M	84.5 M	-57.5 M	-38.4 M	-110 M	-37.1 M	2.13 M	47.3 M	109 M	-28.4 M	93 K	-657 K
Tangible Asset Value	800 M	-166 M	-82.1 M	-44 M	-49.1 M	-195 M	20.7 M	179 M	312 M	371 M	325 M	621 M	789 M	191 M	194 M	15.9 M	13.8 M	6.14 M
Net Current Asset Value, NCAV	-452 M	-785 M	-619 M	-521 M	-519 M	-529 M	-531 M	-239 M	-112 M	-56.9 M	-150 M	-166 M	-59.5 M	46.6 M	109 M	-28.4 M	92 K	-659 K
Invested Capital	1.05 B	1.31 B	1.11 B	809 M	821 M	654 M	226 M	297 M	86.8 M	123 M	44.1 M	78.6 M	68 M	85.9 M	144 M	-826 K	10.7 M	3.2 M
Average Receivables	40.9 M	-	-	-	-	-	-	-	-	-	12.8 M	12.8 M	-	-	-	-	-	-
Average Payables	60.1 M	84.6 M	99.8 M	90 M	102 M	97.1 M	80.2 M	53.5 M	14.3 M	12.7 M	15.6 M	21.1 M	16.7 M	8.62 M	26.9 M	32.3 M	17.6 M	-
Average Inventory	225 M	235 M	240 M	203 M	155 M	131 M	94 M	58.1 M	51.5 M	33 M	16 M	15.8 M	12.2 M	6.6 M	3.25 M	2.51 M	1.65 M	-
Days Sales Outstanding	21.8	-	-	-	-	-	-	-	-	-	-	29.4	-	-	-	-	-	-
Days Payables Outstanding	48.4	93.9	129	115	184	558	287	476	149	115	358	166	347	943	820	8.02 K	19.2 K	-
Days Of Inventory On Hand	205	315	310	275	384	633	489	348	401	631	335	187	189	1.45 K	270	537	1.89 K	-
Receivables Turnover	16.7	-	-	-	-	-	-	-	-	-	-	12.4	-	-	-	-	-	-
Payables Turnover	7.53	3.89	2.83	3.19	1.99	0.655	1.27	0.767	2.46	3.17	1.02	2.2	1.05	0.387	0.445	0.045	0.019	-
Inventory Turnover	1.78	1.16	1.18	1.33	0.952	0.577	0.746	1.05	0.91	0.578	1.09	1.95	1.93	0.251	1.35	0.679	0.193	-
Return On Equity, ROE	0.337	0.135	0.143	0.532	0.856	-1.27	-2	-0.724	-0.179	-0.039	0.042	-0.228	0.023	0.035	0.228	0.427	0.496	-
Capex Per Share	2.2	1.56	1.92	1.14	2.62	0.471	2.84	0.892	0.257	0.438	0.46	0.67	0.426	0.143	0.183	0.311	0.122	-

Alle Zahlen in RUB-Währung

Schlüsselkennzahlen Vierteljährlich Институт стволовых клеток человека

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q3
Operating Cash Flow Per Share	0.001	0.001	0.003	0.003	0.0	0.0	0.001	0.001	0.0	0.0	2.71	0.001	0.51	0.0	-	0.001	-	-0.0	-	0.001	0.0	0.0	-0.0	-0.0	0.001	0.001	0.54	-0.173	-0.0	-0.0	1.88	-1.11	-	-0.316	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Free Cash Flow Per Share	0.0	0.0	0.002	0.002	-0.0	-0.0	0.001	0.001	-0.0	-0.0	0.763	0.001	-0.225	-0.0	-	0.001	-	-0.001	-	-0.0	0.0	0.0	-0.0	-0.0	-0.0	-0.0	0.323	-0.854	-0.002	-0.001	1.2	-1.2	-	-0.316	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Cash Per Share	0.005	0.005	0.008	0.008	0.005	0.005	0.003	0.003	0.001	0.001	0.003	0.002	0.001	0.001	0.002	0.001	0.003	0.002	2.54	0.002	0.002	0.002	0.003	0.003	0.003	0.003	1.72	2.66	0.004	0.006	5.04	4.75	-	2.39	0.003	0.003	0.003	0.002	0.002	0.002	0.003	2.62	0.001	0.001	-	1.16	-
Price To Sales Ratio	15.3 K	15.3 K	15.5 K	15.5 K	18.4 K	18.4 K	22.2 K	22.2 K	25.6 K	29.6 K	13.5	25.1 K	5.01	10.1 K	4.99	8.13 K	2.98	3.87 K	0.002	4.94 K	3.49 K	3.6 K	3.4 K	3.93 K	4.86 K	4.63 K	6.07	7.84	8.04	9.39	12.9	16.6	-	21.3	9.87	9.68	9.23 K	9.18 K	8.91	9.91	12.2 K	10.9	14.3 K	13.2 K	-	8.59	-
Dividend Yield	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue Per Share	0.005	0.005	0.005	0.005	0.004	0.004	0.003	0.003	0.003	0.003	8.5	0.004	7.64	0.004	7.64	0.004	8.66	0.003	6.04 K	0.003	0.003	0.003	0.002	0.002	0.002	0.002	1.9	1.67	1.49	1.53	1.4	1.1	-	1.25	1.06	1.06	0.001	0.001	1.23	1.23	0.001	1.41	0.001	0.001	-	1.61	-
Net Income Per Share	0.001	0.001	0.001	0.001	0.0	0.0	0.0	0.0	0.0	0.0	0.147	-0.0	0.384	0.0	0.384	0.0	0.158	0.0	1.23 K	0.0	0.0	0.0	-0.0	-0.0	0.0	0.0	-1.11	0.331	-0.0	-0.0	-0.084	-0.557	-	-0.097	-0.0	-0.0	0.0	0.0	-0.0	-0.0	0.0	0.721	-0.0	-0.0	-	0.281	-
Book Value Per Share	0.013	0.013	0.013	0.013	0.011	0.011	0.006	0.006	0.006	0.006	0.006	0.005	0.006	0.006	0.006	0.006	0.007	0.007	4.94	0.005	0.003	0.003	0.002	0.002	0.003	0.003	1.71	2.77	0.002	0.003	3.18	3.34	-	4.7	0.005	0.005	0.006	0.006	0.006	0.006	0.006	10.8	0.005	0.011	-	9.8	-
Tangible Book Value Per Share	0.011	0.011	0.011	0.011	0.001	0.009	-0.002	0.005	-0.001	0.004	-0.001	0.004	-0.001	0.004	-0.001	0.004	0.0	0.005	-0.655	0.003	-0.003	0.001	-0.003	-0.0	-0.002	-0.0	0.276	1.79	0.002	0.002	2.39	3.04	-	4.08	0.004	0.005	0.005	0.006	0.005	0.005	0.005	10.7	0.005	0.01	-	9.49	-
Shareholders Equity Per Share	0.006	0.006	0.007	0.007	0.005	0.005	0.004	0.004	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	0.003	1.32	0.001	0.002	0.002	0.0	0.0	0.002	0.002	0.683	1.79	0.001	0.002	2.05	2.13	-	3.74	0.004	0.004	0.005	0.005	0.005	0.005	0.006	10.8	0.005	0.011	-	9.8	-
Interest Debt Per Share	0.011	0.011	0.01	0.01	0.011	0.011	0.009	0.009	0.007	0.007	0.494	0.007	0.392	0.006	0.392	0.007	0.474	0.007	222	0.006	0.007	0.007	0.005	0.005	0.005	0.005	5.63	5.71	0.006	0.006	4.84	5.23	-	1.59	0.002	0.002	0.002	0.002	0.001	0.001	0.002	1.62	0.002	0.002	-	2.12	-
Market Cap	5.7 T	5.7 T	5.8 T	5.8 T	5.72 T	5.72 T	6.85 T	6.85 T	6.65 T	7.69 T	8.43 T	7.82 T	2.79 T	2.8 T	2.78 T	2.56 T	1.88 T	876 B	974 M	1.11 T	672 B	694 B	597 B	690 B	713 B	679 B	862 M	982 M	900 B	1.08 T	1.35 B	1.37 B	-	1.99 B	784 B	769 B	701 B	698 B	825 B	917 B	1.07 T	1.16 B	1.46 T	1.34 T	-	1.04 B	-
Enterprise Value	5.7 T	5.7 T	5.8 T	5.8 T	5.72 T	5.72 T	6.85 T	6.85 T	6.65 T	7.69 T	8.43 T	7.82 T	2.79 T	2.8 T	2.78 T	2.56 T	1.88 T	876 B	1.31 B	1.11 T	672 B	694 B	597 B	690 B	713 B	679 B	1.17 B	1.29 B	900 B	1.08 T	1.41 B	1.48 B	52 M	2.08 B	784 B	769 B	701 B	698 B	825 B	917 B	1.07 T	1.22 B	1.46 T	1.34 T	111 M	1.19 B	85.8 M
P/E Ratio	34.3 K	34.3 K	21.2 K	21.2 K	89.8 K	89.8 K	162 K	162 K	133 K	154 K	196	-484 K	24.9	71.1 K	24.8	3.07 M	40.9	6.05 K	0.003	16.8 K	6.54 K	6.76 K	-4.43 K	-5.12 K	10.7 K	10.2 K	-2.59	9.9	-9.21 K	-13.6 K	-53.8	-8.22	-	-68.5	-5.77 K	-5.66 K	21.4 K	21.3 K	-8.85 K	-9.84 K	15.9 K	5.34	-28 K	-25.7 K	-	12.3	-
P/OCF Ratio	101 K	101 K	30.4 K	30.4 K	218 K	218 K	79.2 K	79.2 K	281 K	325 K	42.4	68.8 K	75.1	105 K	-	41.5 K	-	-25.1 K	-	14.6 K	44.2 K	45.7 K	-19.5 K	-22.6 K	17.7 K	16.9 K	21.3	-75.8	-45.3 K	-39.5 K	9.6	-16.5	-	-84.1	31.6 K	31 K	-31.2 K	-31 K	-58.7 K	-	32.1 K	-	194 K	-	-	-	-
P/FCF Ratio	210 K	210 K	47.7 K	47.7 K	-877 K	-877 K	102 K	102 K	-266 K	-307 K	151	122 K	-170	-26.6 M	-	59 K	-	-14.8 K	-	-173 K	60.2 K	62.1 K	-210 K	-243 K	-139 K	-133 K	35.6	-15.3	-6 K	-25.3 K	15.1	-15.3	-	-84.1	42.3 K	41.5 K	-27.1 K	-27 K	-32 K	-	37.4 K	-	87.1 K	-	-	-	-
P/B Ratio	13.2 K	13.2 K	11.6 K	11.6 K	15 K	15 K	20.1 K	20.1 K	24.1 K	27.8 K	35.9 K	33.3 K	12.5 K	12.6 K	14.3 K	13.2 K	8.7 K	4.05 K	9.87	10 K	4.37 K	4.52 K	22.1 K	25.5 K	6.13 K	5.84 K	16.8	7.31	8.22 K	8.06 K	8.8	8.57	-	7.1	2.72 K	2.67 K	1.97 K	1.96 K	2.43 K	2.7 K	2.38 K	1.43	4.15 K	1.7 K	-	1.41	-
EV/Sales	15.3 K	15.3 K	15.5 K	15.5 K	18.4 K	18.4 K	22.2 K	22.2 K	25.6 K	29.6 K	13.5	25.1 K	5.01	10.1 K	4.99	8.13 K	2.98	3.87 K	0.003	4.94 K	3.49 K	3.61 K	3.4 K	3.93 K	4.86 K	4.63 K	8.23	10.3	8.04	9.39	13.5	17.9	0.477	22.2	9.87	9.68	9.23 K	9.18 K	8.91	9.91	12.2 K	11.6	14.3 K	13.2 K	-	9.83	-
EV/EBITDA	59.4 K	59.4 K	60.4 K	60.4 K	85 K	85 K	207 K	207 K	165 K	191 K	117	161 K	34.8	61.1 K	63.9	57.9 K	52	10.8 K	0.017	17.3 K	14.1 K	14.6 K	9.56 K	11 K	66.3 K	63.2 K	-21.1	39.6	-49.2 K	-39.4 K	415	-29.9	-0.884	-448	-24.4 K	-23.9 K	-194 K	-193 K	-72 K	-80 K	-1.11 M	16.5	173 K	159 K	-	37.1	-
EV/OCF	101 K	101 K	30.4 K	30.4 K	218 K	218 K	79.2 K	79.2 K	281 K	325 K	42.4	68.8 K	75.1	105 K	-	41.5 K	-	-25.1 K	-	14.6 K	44.3 K	45.7 K	-19.6 K	-22.6 K	17.7 K	16.9 K	28.9	-99.9	-45.3 K	-39.5 K	10	-17.8	29.1	-87.8	31.6 K	31 K	-31.2 K	-31 K	-58.7 K	-	32.1 K	-	194 K	-	-	-	-
Earnings Yield	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.001	-0.0	0.01	0.0	0.01	0.0	0.006	0.0	94.7	0.0	0.0	0.0	-0.0	-0.0	0.0	0.0	-0.096	0.025	-0.0	-0.0	-0.005	-0.03	-	-0.004	-0.0	-0.0	0.0	0.0	-0.0	-0.0	0.0	0.047	-0.0	-0.0	-	0.02	-
Free Cash Flow Yield	0.0	0.0	0.0	0.0	-0.0	-0.0	0.0	0.0	-0.0	-0.0	0.007	0.0	-0.006	-0.0	-	0.0	-	-0.0	-	-0.0	0.0	0.0	-0.0	-0.0	-0.0	-0.0	0.028	-0.065	-0.0	-0.0	0.066	-0.066	-	-0.012	0.0	0.0	-0.0	-0.0	-0.0	-	0.0	-	0.0	-	-	-	-
Debt To Equity	1.82	1.82	1.57	1.57	2.13	2.13	2.44	2.44	2.25	2.25	2.63	2.63	2.14	2.14	2.51	2.51	2.41	2.41	4.3	3.83	3.38	3.38	13.9	13.9	3.47	3.47	8.09	3.13	3.94	3.28	2.25	2.43	0.368	0.413	0.399	0.399	0.329	0.329	0.292	0.292	0.3	0.146	0.367	0.172	0.175	0.21	0.156
Debt To Assets	0.315	0.315	0.309	0.309	0.345	0.345	0.407	0.407	0.356	0.356	0.355	0.355	0.318	0.318	0.323	0.323	0.329	0.329	0.303	0.303	0.364	0.364	0.333	0.333	0.36	0.36	0.393	0.403	0.4	0.393	0.333	0.396	0.099	0.142	0.138	0.138	0.139	0.139	0.123	0.123	0.161	0.098	0.177	0.121	0.124	0.143	0.111
Net Debt To EBITDA	4.37	4.37	2.52	2.52	6.68	6.68	19	19	14	14	0.006	8.73	0.005	9.35	0.009	8.61	0.01	4.48	0.004	5.2	9.69	9.69	4.96	4.96	30.3	30.3	-5.55	9.55	-13.6	-3.85	17.8	-2.18	-0.884	-18.8	-1.99	-1.99	-16.3	-16.3	-2.44	-2.44	-43.1	0.937	13.1	15.4	-	4.69	-
Current Ratio	1.88	1.88	1.99	1.99	2.09	2.09	1.74	1.74	1.98	1.98	1.77	1.77	1.32	1.32	1.04	1.04	1.41	1.41	1.05	1.05	1.22	1.22	1.15	1.15	0.804	0.804	0.705	0.934	0.946	1.27	1.18	1.28	0.699	0.697	0.863	0.863	0.953	0.953	0.895	0.895	0.939	0.852	0.662	0.783	1.05	0.826	0.895
Interest Coverage	-	-	-	-	-	-	-	-	-	-	0.779	-	1.55	-	1.84	-	1.39	-	5.97	-	-	-	-	-	-	-	-0.727	0.461	-	-	-2.33	-21.9	-11.9	1.07	-	-	-	-	-	-	-	0.871	-	-	-	11.4	-
Income Quality	1.36	1.36	2.79	2.79	1.64	1.64	8.19	8.19	1.89	1.89	-24.6	-28.1	1.88	2.71	-	297	-	-0.963	-	4.6	0.592	0.592	0.907	0.907	2.43	2.43	-0.513	-0.515	0.813	1.37	-11.5	1.72	-0.032	3.31	-0.73	-0.73	-2.75	-2.75	0.603	-	1.99	-	-0.578	-	-	-	-
Sales General And Administrative To Revenue	0.047	0.047	0.054	0.054	0.039	0.039	0.036	0.036	0.033	0.033	-	0.037	-	0.026	-	0.04	-	0.029	-	0.074	0.05	0.05	0.055	0.055	0.045	0.045	0.023	0.022	0.0	0.0	0.088	0.238	0.142	0.214	0.0	0.0	0.123	0.123	0.0	0.0	0.112	0.23	0.064	0.064	-	0.174	-
Intangibles To Total Assets	0.066	0.066	0.069	0.069	0.316	0.067	0.36	0.073	0.33	0.071	0.312	0.074	0.328	0.078	0.304	0.077	0.285	0.076	0.3	0.091	0.333	0.109	0.281	0.118	0.313	0.207	0.102	0.07	0.063	0.052	0.057	0.023	0.064	0.057	0.057	0.018	0.061	0.025	0.027	0.027	0.053	0.005	0.023	0.015	0.08	0.022	0.021
Capex To Operating Cash Flow	0.519	0.519	0.363	0.363	1.25	1.25	0.223	0.223	2.06	2.06	0.719	0.438	1.44	1	-	0.297	-	-0.701	-	1.08	0.265	0.265	-0.907	-0.907	1.13	1.13	0.402	-3.94	-6.55	-0.563	0.363	-0.082	4.98	-	0.253	0.253	-0.151	-0.151	-0.836	-	0.141	-	1.22	-	-	-	-
Capex To Revenue	0.079	0.079	0.186	0.186	0.105	0.105	0.062	0.062	0.187	0.187	0.229	0.16	0.096	0.096	-	0.058	-	0.108	-	0.367	0.021	0.021	0.158	0.158	0.309	0.309	0.115	0.408	0.001	0.0	0.487	0.082	0.082	-	0.0	0.0	0.045	0.045	0.0	-	0.054	-	0.09	-	-	-	-
Capex To Depreciation	1.48	1.48	5.19	5.19	1.48	1.48	2.03	2.03	2.83	2.83	3.22	2.24	1.46	1.46	-	0.923	-	1.39	-	5.71	0.259	0.259	12.3	12.3	3.61	3.61	0.783	5.56	216	1.56	9.89	0.871	2	-	0.924	0.924	0.536	0.536	2.07	-	0.685	-	1.56	-	-	-	-
Stock Based Compensation To Revenue	0.001	0.001	0.001	0.001	0.001	0.001	0.002	0.002	0.016	0.016	-	0.018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Graham Number	0.009	0.009	0.012	0.012	0.005	0.005	0.003	0.003	0.003	0.003	0.103	0.002	0.163	0.003	0.152	0.0	0.103	0.006	191	0.003	0.004	0.004	0.002	0.002	0.003	0.003	4.13	3.65	0.003	0.003	1.97	5.17	-	2.86	0.006	0.006	0.003	0.003	0.006	0.006	0.005	13.2	0.004	0.006	-	7.88	-
Return On Invested Capital, ROIC	0.038	0.038	0.036	0.036	0.022	0.022	0.752	0.752	0.021	0.021	19.8	0.019	40.9	-5.18	53.4	0.023	31.3	-7.58	105	-14.8	0.034	0.034	0.107	0.107	0.598	0.598	-0.01	0.01	-0.033	-0.056	-0.043	-0.076	-0.118	0.008	-0.078	-0.078	-0.013	-0.013	-0.038	-0.038	-0.008	0.003	0.0	0.0	-	0.044	-
Return On Tangible Assets, ROTA	0.018	0.018	0.029	0.029	0.01	0.007	0.008	0.006	0.011	0.008	9.01	-0.003	27.8	0.007	26.6	0.0	10.1	0.025	94.2	0.013	0.027	0.02	-0.042	-0.034	0.022	0.019	-0.088	0.026	-0.024	-0.019	-0.006	-0.043	-0.079	-0.009	-0.043	-0.042	0.01	0.01	-0.03	-0.03	0.021	0.045	-0.018	-0.012	-	0.02	-
Graham Net Net	-0.013	-0.013	-0.011	-0.011	-0.014	-0.013	-0.012	-0.012	-0.012	-0.012	-0.012	-0.011	-0.011	-0.011	-0.012	-0.011	-0.011	-0.01	-10	-0.01	-0.012	-0.012	-0.01	-0.009	-0.009	-0.008	-9.79	-7.99	-0.008	-0.005	-5.21	-4.42	-	-3.82	-0.003	-0.003	-0.002	-0.002	-0.002	-0.002	-0.002	-2.55	-0.003	-0.003	-	-3.35	-
Working Capital	476 M	476 M	556 M	556 M	497 M	497 M	294 M	294 M	289 M	289 M	286 M	286 M	128 M	128 M	19.8 M	19.8 M	190 M	190 M	22.2 M	22.2 M	90.7 M	90.7 M	61 M	61 M	-115 M	-115 M	-165 M	-30.1 M	-26.9 M	135 M	84.5 M	112 M	-126 M	-126 M	-57.5 M	-57.5 M	-17.1 M	-17.1 M	-38.4 M	-38.4 M	-20.4 M	-50.2 M	-110 M	-61.3 M	7.96 M	-48.7 M	-25.3 M
Tangible Asset Value	787 M	787 M	800 M	800 M	69.1 M	654 M	-166 M	420 M	-90.8 M	362 M	-82.1 M	332 M	-40.6 M	333 M	-44 M	298 M	36 M	367 M	-49.1 M	244 M	-216 M	103 M	-195 M	-11.4 M	-156 M	-36.6 M	20.7 M	134 M	114 M	151 M	179 M	228 M	251 M	306 M	312 M	345 M	384 M	414 M	400 M	400 M	410 M	801 M	346 M	773 M	755 M	711 M	663 M
Net Current Asset Value, NCAV	-539 M	-539 M	-452 M	-452 M	-591 M	-591 M	-785 M	-785 M	-681 M	-681 M	-619 M	-619 M	-518 M	-518 M	-521 M	-521 M	-449 M	-449 M	-519 M	-519 M	-666 M	-666 M	-529 M	-529 M	-457 M	-457 M	-531 M	-408 M	-428 M	-274 M	-239 M	-215 M	-161 M	-175 M	-112 M	-112 M	-63.9 M	-63.9 M	-56.9 M	-56.9 M	-62.2 M	-104 M	-150 M	-108 M	-163 M	-115 M	-62.7 M
Invested Capital	1.01 B	1.01 B	1.05 B	1.05 B	1.54 B	957 M	1.31 B	725 M	1.14 B	687 M	1.11 B	699 M	925 M	551 M	809 M	467 M	999 M	668 M	821 M	528 M	962 M	644 M	654 M	471 M	506 M	386 M	226 M	326 M	325 M	351 M	297 M	225 M	15.9 M	11.5 M	86.8 M	53.9 M	134 M	104 M	93.8 M	93.8 M	106 M	61.7 M	23.7 M	59 M	214 M	73.5 M	33.5 M
Average Receivables	86 M	83.9 M	81.8 M	40.9 M	52 M	52 M	33.9 M	33.9 M	33.3 M	74.8 M	83.1 M	90.6 M	97.8 M	48.8 M	45.1 M	45.1 M	27 M	27 M	30.9 M	30.9 M	24.6 M	24.6 M	21.9 M	21.9 M	24.8 M	24.8 M	-	-	34.2 M	34.2 M	15.9 M	15.9 M	-	-	11.8 M	11.8 M	12.9 M	22.4 M	18.9 M	9.45 M	-	27.9 M	27.9 M	-	-	-	-
Average Payables	28 M	40.7 M	53.4 M	100 M	89.7 M	49.8 M	50.4 M	72.5 M	82.9 M	78.5 M	69.1 M	62.8 M	89.8 M	93.6 M	66.4 M	69.8 M	68.1 M	57.4 M	61.9 M	57 M	73 M	97.2 M	101 M	82.6 M	78.1 M	71.8 M	64.9 M	78.7 M	91.6 M	85.3 M	59.1 M	41.5 M	35.2 M	18.6 M	17.4 M	13.1 M	8.04 M	4.67 M	3.97 M	11.2 M	133 M	127 M	99.3 M	98.6 M	93.2 M	-	-
Average Inventory	252 M	239 M	226 M	222 M	218 M	221 M	224 M	226 M	227 M	237 M	246 M	250 M	253 M	244 M	234 M	251 M	269 M	221 M	173 M	163 M	153 M	145 M	138 M	122 M	105 M	115 M	98.3 M	70.6 M	65.6 M	63.4 M	53.1 M	52.3 M	31.3 M	26 M	52.1 M	53.4 M	54.6 M	52.8 M	50.9 M	32.8 M	13.3 M	13.6 M	15.5 M	17.8 M	17.9 M	-	-
Days Sales Outstanding	20.8	20.8	19.7	19.7	-	30.1	-	19.8	-	23	0.012	24	0.016	31.6	-	25.7	-	21.5	-	24.7	-	23	-	22.4	-	30.4	-	-	-	0.053	-	34.6	-	-	-	0.027	-	30.7	0.018	0.018	-	-	49.2	-	-	-	-
Days Payables Outstanding	27.1	27.1	40.4	40.4	161	36	45.5	23.1	104	51	0.021	27	0.02	73	0.022	19.7	0.02	87.2	0.029	59.3	168	168	419	276	215	179	164	408	291	188	397	124	110	128	47.6	38	40.7	20.4	14.2	14.2	92.8	315	40.2	1.29 K	-	384	-
Days Of Inventory On Hand	244	244	171	171	239	239	153	153	212	212	0.05	184	0.056	206	0.052	130	0.051	731	0.061	250	352	352	476	476	265	265	279	520	198	142	291	170	131	-	129	129	207	207	182	182	74.2	15.3	101	107	-	34.3	-
Receivables Turnover	4.33	4.33	4.57	4.57	-	2.99	-	4.55	-	3.91	7.52 K	3.75	5.68 K	2.85	-	3.5	-	4.19	-	3.65	-	3.91	-	4.01	-	2.96	-	-	-	1.68 K	-	2.6	-	-	-	3.37 K	-	2.94	4.9 K	4.9 K	-	-	1.83	-	-	-	-
Payables Turnover	3.32	3.32	2.23	2.23	0.56	2.5	1.98	3.9	0.868	1.77	4.29 K	3.34	4.5 K	1.23	4.15 K	4.56	4.58 K	1.03	3.1 K	1.52	0.537	0.537	0.215	0.327	0.419	0.504	0.549	0.221	0.309	0.479	0.227	0.724	0.82	0.704	1.89	2.37	2.21	4.42	6.34	6.34	0.97	0.286	2.24	0.07	-	0.235	-
Inventory Turnover	0.369	0.369	0.526	0.526	0.376	0.376	0.59	0.59	0.424	0.424	1.79 K	0.488	1.59 K	0.437	1.73 K	0.691	1.77 K	0.123	1.48 K	0.361	0.256	0.256	0.189	0.189	0.339	0.339	0.322	0.173	0.454	0.634	0.309	0.529	0.686	-	0.7	0.7	0.434	0.434	0.494	0.494	1.21	5.88	0.891	0.844	-	2.62	-
Return On Equity, ROE	0.096	0.096	0.137	0.137	0.042	0.042	0.031	0.031	0.045	0.045	45.9	-0.017	125	0.044	144	0.001	53.2	0.168	934	0.15	0.167	0.167	-1.25	-1.25	0.143	0.143	-1.62	0.185	-0.223	-0.148	-0.041	-0.261	-0.278	-0.026	-0.118	-0.118	0.023	0.023	-0.069	-0.069	0.037	0.067	-0.037	-0.017	-	0.029	-
Capex Per Share	0.0	0.0	0.001	0.001	0.0	0.0	0.0	0.0	0.001	0.001	1.95	0.001	0.735	0.0	-	0.0	-	0.0	-	0.001	0.0	0.0	0.0	0.0	0.001	0.001	0.217	0.682	0.002	0.0	0.683	0.091	-	-	0.0	0.0	0.0	0.0	0.0	-	0.0	-	0.0	-	-	-	-

Alle Zahlen in RUB-Währung

Finanzberichterstattung ist das wichtigste Instrument, mit dem Unternehmen Interessengruppen über ihre finanzielle Lage, Geschäftsergebnisse und Veränderungen in der Kapitalstruktur informieren. Sie ist gewissermaßen die „Sprache der Wirtschaft“, die von Investoren, Gläubigern, Steuerbehörden und anderen Akteuren des wirtschaftlichen Umfelds verstanden wird.

Hauptarten der Finanzberichte Институт стволовых клеток человека ISKJ

Gewinn- und Verlustrechnung
Zeigt Erträge, Aufwendungen sowie den Gewinn oder Verlust für einen bestimmten Zeitraum. Sie ermöglicht die Bewertung der Rentabilität eines Unternehmens.
Bilanz
Stellt Vermögenswerte, Verbindlichkeiten und Eigenkapital eines Unternehmens zu einem bestimmten Stichtag dar. Sie ist eine Momentaufnahme dessen, was das Unternehmen besitzt und schuldet.
Vermögenswerte – alles, was dem Unternehmen gehört (Bargeld, Anlagen, Gebäude, Forderungen usw.).
Verbindlichkeiten – Schulden und andere externe Finanzierungsquellen.
Eigenkapital – eigenes Kapital der Eigentümer und einbehaltene Gewinne.
Kapitalflussrechnung
Zeigt, woher das Unternehmen Geld erhält und wie es dieses in drei Bereichen verwendet: operative, Investitions- und Finanzierungstätigkeit.

Internationale Rechnungslegungsstandards

IFRS – Internationale Rechnungslegungsstandards, relevant für börsennotierte und multinationale Unternehmen.
GAAP – Allgemein anerkannte Rechnungslegungsgrundsätze in den USA.
RAS – Russische Rechnungslegungsstandards, die im Inland angewendet werden.

Die Finanzberichterstattung Институт стволовых клеток человека spielt eine entscheidende Rolle für Investoren, da sie eine objektive Informationsquelle über den aktuellen Zustand eines Unternehmens darstellt. Anhand der Berichte lässt sich erkennen, ob ein Unternehmen wächst, stagniert oder Marktanteile verliert. Dadurch können Investoren frühzeitig vielversprechende oder risikobehaftete Anlagen identifizieren.

Darüber hinaus bilden Finanzdaten die Grundlage für Prognosen zukünftiger Erträge. Historische Entwicklungen bei Umsatz, Gewinn und Cashflows helfen, potenzielle Dividenden, Kurssteigerungen und das Gesamtrisiko einer Investition einzuschätzen.

Transparente und ehrliche Berichterstattung ist auch ein Zeichen für die Reife und Verantwortlichkeit eines Unternehmens. Eine solche Offenheit stärkt das Vertrauen der Investoren und erleichtert Investitionsentscheidungen – insbesondere beim Vergleich mehrerer Unternehmen.

Schließlich ermöglicht die Finanzberichterstattung eine fundierte vergleichende Analyse. Sie erlaubt es, Unternehmen hinsichtlich Rentabilität, Verschuldung, Marge und anderen wichtigen Kennzahlen gegenüberzustellen – was besonders wichtig bei der Auswahl optimaler Investitionsmöglichkeiten innerhalb einer Branche oder eines Marktsegments ist.

Finanzberichte anderer Aktien in der Pharmaeinzelhändler

Name	Preis	% 24h	Marktkapitalisierung	Land
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Pharming Group N.V. PHAR	$ 17.91	-1.0 %	$ 7.59 B	Niderland
Arbutus Biopharma Corporation ABUS	$ 4.78	-0.31 %	$ 793 M	Canada
Aclaris Therapeutics ACRS	$ 3.03	-0.49 %	$ 234 M	USA
InflaRx N.V. IFRX	$ 1.09	-4.82 %	$ 152 M	Germany
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Aptorum Group Limited APM	$ 1.15	-1.71 %	$ 6.27 M	China
Ampio Pharmaceuticals AMPE	-	-11.43 %	$ 502 K	USA
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Ascendis Pharma A/S ASND	$ 209.39	-1.61 %	$ 5 B	Danmark
Aptevo Therapeutics APVO	$ 0.6	-35.8 %	$ 166 K	USA
Alterity Therapeutics Limited ATHE	$ 3.12	0.81 %	$ 7.51 B	Australia
BioVie BIVI	$ 1.2	-5.51 %	$ 1.77 M	USA
Athersys ATHX	-	3.77 %	$ 22.4 M	USA
Avenue Therapeutics ATXI	-	-52.27 %	$ 4.45 M	USA
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	$ 0.22	24.46 %	$ 479 M	Israel
Acasti Pharma ACST	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-	-15.15 %	$ 60.3 M	Britain
BioDelivery Sciences International BDSI	-	-4.8 %	$ 255 M	USA
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
BioNTech SE BNTX	$ 94.72	-0.33 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	$ 27.09	1.04 %	$ 1.31 B	USA
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
Anika Therapeutics ANIK	$ 9.6	1.27 %	$ 141 M	USA
Bellicum Pharmaceuticals BLCM	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	-	-	$ 546 M	USA
Arena Pharmaceuticals ARNA	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	-	2.71 %	$ 14 M	USA
Calithera Biosciences CALA	-	-10.95 %	$ 876 K	USA
Axon Enterprise AXON	$ 584.81	-1.07 %	$ 44.3 B	USA
Cellectar Biosciences CLRB	$ 2.53	-8.33 %	$ 30.9 M	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	$ 2.44	-3.56 %	$ 15.3 M	USA
AstraZeneca PLC AZN	$ 92.79	0.37 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Catalyst Biosciences CBIO	$ 12.33	-0.29 %	$ 812 M	USA
Brickell Biotech BBI	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	$ 9.1	1.0 %	$ 1.48 B	Britain
Celldex Therapeutics CLDX	$ 26.29	-2.01 %	$ 1.69 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	$ 11.07	2.45 %	$ 716 M	USA

Институт стволовых клеток человека Finanzdaten 2006-2025 | ISKJ

Schlüsselkennzahlen Институт стволовых клеток человека

Operating Cash Flow Per Share

Free Cash Flow Per Share

Cash Per Share

Price To Sales Ratio

Dividend Yield

Payout Ratio

Revenue Per Share

Net Income Per Share

Book Value Per Share

Tangible Book Value Per Share

Shareholders Equity Per Share

Interest Debt Per Share

Market Cap

Enterprise Value

P/E Ratio

P/OCF Ratio

P/FCF Ratio

P/B Ratio

EV/Sales

EV/EBITDA

EV/OCF

Earnings Yield

Free Cash Flow Yield

Debt To Equity

Debt To Assets

Net Debt To EBITDA

Current Ratio

Interest Coverage

Income Quality

Sales General And Administrative To Revenue

Intangibles To Total Assets

Capex To Operating Cash Flow

Capex To Revenue

Capex To Depreciation

Stock Based Compensation To Revenue

Graham Number

Return On Invested Capital, ROIC

Return On Tangible Assets, ROTA

Graham Net Net

Working Capital

Tangible Asset Value

Net Current Asset Value, NCAV

Invested Capital

Average Receivables

Average Payables

Average Inventory

Days Sales Outstanding

Days Payables Outstanding

Days Of Inventory On Hand

Receivables Turnover

Payables Turnover

Inventory Turnover

Return On Equity, ROE

Capex Per Share